{"id":"W4416588990","doi":"10.1016/j.conctc.2025.101574","title":"Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease","year":2025,"lang":"en","type":"article","venue":"Contemporary Clinical Trials Communications","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Western University","funders":"Envision; Allergan; Celltrion; Celgene; Amgen; Pfizer; Viropharma; Biogen","keywords":"Vedolizumab; Disease; Phases of clinical research; Phase (matter); Maximum tolerated dose","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"methods","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"protocol","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05419802,0.005834255,0.006880069,0.002111311,0.0037932,0.003709337,0.004494871,0.006935738,0.02545778],"category_scores_gemma":[0.03652716,0.003926979,0.003308428,0.00227325,0.005992312,0.002860227,0.002043225,0.01093769,0.01155514],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002315173,"about_ca_system_score_gemma":0.009925874,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009224711,"about_ca_topic_score_gemma":0.002692499,"domain_scores_codex":[0.9619485,0.02509855,0.002306483,0.004153708,0.004519388,0.001973354],"domain_scores_gemma":[0.9893985,0.003020664,0.001537715,0.001364607,0.001853722,0.002824705],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7105942,0.03035207,0.007401112,0.01507341,0.002014708,0.001510019,0.001458441,0.003712719,0.01296476,0.0320555,0.06568475,0.1171783],"study_design_scores_gemma":[0.7554868,0.07170624,0.008542938,0.003229627,0.001466315,0.0005453794,0.0003021045,0.004490278,0.002452337,0.01104457,0.1403839,0.0003494101],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.01459073,0.006064178,0.01452235,0.005010508,0.005758914,0.9414462,0.004671932,0.0004742024,0.007460902],"genre_scores_gemma":[0.02411177,0.001735043,0.01803107,0.005497648,0.001210153,0.9455138,0.001115886,0.00005853569,0.002726013],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.05419802,"threshold_uncertainty_score":0.28663,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2741327899154942,"score_gpt":0.4753525915857392,"score_spread":0.201219801670245,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}